African Americans are less likely to receive curative treatment for hepatocellular carcinoma

Table 3 Multinomial logistic regression to evaluate disparities in treatment for hepatocellular carcinoma based on payer^{1, 2}

Intervention	Race	Odds ratio	Confidence interval
Liver Transplant	African-American	Reference
	Caucasian	2.66	1.92-3.68
	Hispanic	2.18	1.40-3.39
	Other/unknown	2.41	1.62-3.61
Resection	African-American	Reference
	Caucasian	1.82	1.48-2.23
	Hispanic	1.24	0.94-1.64
	Other/unknown	1.79	1.39-2.32
Ablation	African-American	Reference
	Caucasian	1.77	1.36-2.30
	Hispanic	1.46	1.05-2.03
	Other/unknown	2.03	1.47-2.80
TACE	African-American	Reference
	Caucasian	1.15	0.93-1.41
	Hispanic	1.29	0.97-1.72
	Other/unknown	1.19	0.90-1.58

¹Noninvasive treatment is treated as the reference category; ²Model adjusts for age, gender, race, geographic region, hepatitis C, hepatitis B, alcohol, non-alcoholic steatohepatitis, liver decompensation features, and Elixhauser comorbidity score. TACE: Transarterial chemoablation.